Twist Bioscience 将来の成長
Future 基準チェック /16
Twist Bioscienceは、54.5%と17.3%でそれぞれ年率54.5%で利益と収益が成長すると予測される一方、EPSはgrowで53.6%年率。
主要情報
54.5%
収益成長率
53.58%
EPS成長率
| Biotechs 収益成長 | 27.2% |
| 収益成長率 | 17.3% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 05 Aug 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Aug 13
TWST: AI Order Momentum Will Test Sustainability After Equity Raise
Analysts have lifted the Twist Bioscience fair value estimate from $92.50 to $105.30, citing refreshed models that reflect updated revenue expectations, AI-enabled drug discovery order trends, and revised sector assumptions across recent research. Analyst Commentary Recent Street research around Twist Bioscience shows a cluster of higher fair value targets and mostly positive views on execution, with one more cautious voice highlighting valuation risks after a strong share price run.分析記事 • Aug 06
Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104
Shareholders will be ecstatic, with their stake up 35% over the past week following Twist Bioscience Corporation 's...Seeking Alpha • Aug 05
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
Summary Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve. While the outlook is positive, Twist's valuation is now demanding, increasing risk and limiting near-term upside. Read the full article on Seeking Alphaナラティブ更新 • Jul 30
TWST: AI Drug Discovery Hopes Face Sector And Execution Headwinds
The updated analyst price target for Twist Bioscience moves from $71.10 to $92.50 as analysts refresh models around higher assumed revenue growth, a lower discount rate, and a higher future P/E multiple, partly offset by more conservative profit margin expectations. Analyst Commentary Recent Street research on Twist Bioscience points to an active debate on valuation and execution as the stock responds to shifting expectations around growth, margins, and the broader life science tools sector.
ナラティブ更新 • Jul 16
TWST: AI Drug Discovery Demand Will Shape Multi Year Upside Potential
Analysts have raised the fair value estimate for Twist Bioscience to $120 from $95, reflecting updated models that incorporate slightly higher revenue growth assumptions, adjusted profit margin expectations, and a higher future P/E, in line with a series of recent price target increases across the Street. Analyst Commentary Bullish analysts covering Twist Bioscience have been revisiting their models, with a series of higher price targets and positive views on the company’s execution in life science tools and synthetic biology.ナラティブ更新 • Jul 02
TWST: AI Drug Discovery Exposure And Tools Recovery Will Shape Multi Year Outlook
The analyst fair value estimate for Twist Bioscience has been revised from $58.00 to $95.00. This change reflects updated sector views and recent price target increases across the Street.分析記事 • Jun 18
Twist Bioscience (TWST) Stock Looks 42.9% Overvalued After Bullish Analyst Calls
Recent bullish coverage from firms such as Canaccord Genuity, highlighting Twist Bioscience (TWST) silicon-based lab-on-a-chip platform and AI-enabled drug discovery efforts, has pushed Twist Bioscience stock firmly into focus for many investors. See our latest analysis for Twist Bioscience. That bullish research comes after a sharp move in the Twist Bioscience share price. The stock closed at US$82.87, with a 30 day share price return of 66.44% and a 1 year total shareholder return of...ナラティブ更新 • Jun 18
TWST: AI Drug Discovery Hopes Will Be Tested By Sector Headwinds
The analyst fair value estimate for Twist Bioscience has been lifted from $64.38 to $71.10. Analysts point to a higher assumed revenue growth rate, a richer future P/E and sector research that highlights the company’s growing role in next generation drug discovery and development as key factors in the new price target.ナラティブ更新 • Jun 04
TWST: AI Drug Discovery Hopes Will Outrun Earnings Execution Risk
The analyst price target for Twist Bioscience has been revised higher to $64.38 from $63.33. Analysts point to updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E as key drivers of the change.ナラティブ更新 • May 20
TWST: Silicon DNA Platform And Profitability Shift Will Drive Bullish Repricing
Analysts have raised their average price target for Twist Bioscience to about $63.33 from $55.00, citing updated assumptions around profitability, modest tweaks to discount rates and growth, and a lower future P/E multiple as key inputs in their models. Analyst Commentary Recent research on Twist Bioscience centers on how updated profitability assumptions and valuation frameworks translate into higher price targets, with several analysts revising their models over a short period.ナラティブ更新 • Apr 29
TWST: Silicon DNA Platform And Expanded Partnerships Will Shape Balanced Risk Reward Profile
Twist Bioscience's analyst fair value estimate has been reset from $35.63 to $55.00. Analysts point to a series of recent price target increases from firms such as Barclays, Evercore ISI, Guggenheim and Baird as support for the higher range.ナラティブ更新 • Apr 15
TWST: Bispecific Platform Deal And Tools Recovery Will Shape Multi Year Outlook
Twist Bioscience's updated analyst price target remains at $58.00. Recent Street research cites revised assumptions around revenue growth, profitability, and a lower future P/E as key drivers behind the refreshed narrative.
ナラティブ更新 • Mar 30
TWST: Sector Recovery Hopes Will Likely Outpace 2026 Execution Reality
Analysts have lifted the implied fair value estimate for Twist Bioscience by about $5 to roughly $38 per share, citing refreshed models that incorporate updated 2026 frameworks, recovering end markets and multiple avenues for growth reflected in recent price target increases from firms across the diagnostic tools peer group. Analyst Commentary Recent Street research on Twist Bioscience has centered on refreshed 2026 frameworks, sector rotation within diagnostic tools and how quickly end markets are recovering.ナラティブ更新 • Mar 16
TWST: 2026 Tools Recovery And Bispecific Deal Will Support Multi Year Upside
Analysts have raised their average price targets on Twist Bioscience by double digit dollar amounts. Firms such as Baird, Evercore ISI, Barclays, Guggenheim and TD Cowen have cited recovering end markets, improving sentiment into 2026 and multiple avenues for upside to previously derisked growth assumptions.ナラティブ更新 • Mar 02
TWST: 2026 Tools Recovery Framework Will Drive Multi Year Platform Upside
Analysts have lifted their price targets on Twist Bioscience by $8 to $17 per share in recent research, tying the changes to improving tools sector sentiment, recovering end markets into 2026, and what they view as multiple avenues for upside within a clearer multi year growth framework. Analyst Commentary Bullish analysts are clustering around a more constructive view on Twist Bioscience, pointing to a clearer multi year growth framework and a tools sector that they see as recovering into 2026.ナラティブ更新 • Feb 16
TWST: Multi Year Tools Framework Will Drive DNA Synthesis Platform Upside
Analysts have raised their price targets for Twist Bioscience, supporting a fair value move from $42.00 to $58.00. They cite a clearer multi year growth framework, recovering end markets, and a tools focused setup into 2026.ナラティブ更新 • Feb 02
TWST: Sector Recovery Optimism Will Likely Outrun Synthetic Biology Market Realities
Analysts have lifted their price targets on Twist Bioscience by up to about $10, citing improving sentiment into 2026, recovering end markets, and what they see as multiple potential avenues for growth in the tools and synthetic biology businesses, despite some remaining questions on market size. Analyst Commentary Recent research commentary has generally leaned constructive on Twist Bioscience, with several firms lifting their price targets and pointing to tools and synthetic biology as potential growth drivers into 2026.ナラティブ更新 • Jan 19
TWST: Sector Recovery Hopes Will Likely Overstate Synthetic Biology Upside
Analysts have raised their fair value estimate for Twist Bioscience to $33 from $25, citing higher assumed revenue growth, improved profit margins, and future P/E multiples supported by recent price target increases and commentary regarding sector recovery, multi-year growth frameworks, and share gains in DNA synthesis. Analyst Commentary Recent Street research on Twist Bioscience reflects a mix of optimism and restraint, with several firms revisiting their price targets and highlighting both potential upside drivers and key execution questions.分析記事 • Jan 14
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 30%
The Twist Bioscience Corporation ( NASDAQ:TWST ) share price has done very well over the last month, posting an...ナラティブ更新 • Jan 05
TWST: Commercial Execution Will Drive DNA Synthesis Platform Toward Profitable Scale
Analysts have trimmed their price target on Twist Bioscience from $50 to $42 per share. This reflects a slightly higher discount rate and more tempered revenue growth expectations, even as they acknowledge the company’s differentiated DNA synthesis platform, cost leadership, and continued market share gains.ナラティブ更新 • Dec 15
TWST: Silicon DNA Platform And Aggressive Commercial Push Will Drive Share Gains
Analysts have modestly trimmed their price target on Twist Bioscience by a few dollars per share to better reflect lingering questions around the size and timing of synthetic biology opportunities, even as they highlight the company’s differentiated, cost advantaged DNA synthesis platform and ongoing share gains as key drivers of long term upside. Analyst Commentary Bullish analysts emphasize that Twist’s differentiated, technology driven DNA synthesis platform, built on proprietary silicon chip technology, underpins a durable competitive moat that can support premium growth and multiple expansion over time.ナラティブ更新 • Dec 01
TWST: Silicon Chip DNA Platform Will Drive Continued Market Share Gains
Analysts have slightly raised their fair value estimate for Twist Bioscience to $35.63 from $35.57 per share. They cite ongoing market share gains and commercial momentum, even as questions remain about future growth opportunities.ナラティブ更新 • Nov 17
TWST: Silicon Chip Technology Will Drive Future Market Share Gains
Analysts have lowered their price target for Twist Bioscience from $39.43 to $35.57, citing stable yet competitive end markets, slightly reduced growth expectations, and a longer path to profitability. Analyst Commentary Recent research from the Street highlights a mix of optimism and caution in outlooks for Twist Bioscience.ナラティブ更新 • Nov 01
TWST: Share Valuations Will Stabilize As End Markets Remain Strong
Analysts have lowered their price target for Twist Bioscience to $40 from $45, citing stable end markets and improved sentiment as share valuations adjust. Analyst Commentary Bullish Takeaways Bullish analysts highlight that end markets remain stable, which supports reliable performance in the near term.ナラティブ更新 • Oct 18
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have revised Twist Bioscience’s price target downward from $40.00 to $39.43, citing stable end markets and expectations of improving sentiment as the primary rationale for the modest adjustment. Analyst Commentary Recent analyst updates on Twist Bioscience reflect a nuanced perspective on the company’s outlook, highlighting both potential opportunities and ongoing challenges that could influence near-term valuation and long-term growth prospects.分析記事 • Oct 09
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%
Those holding Twist Bioscience Corporation ( NASDAQ:TWST ) shares would be relieved that the share price has rebounded...ナラティブ更新 • Oct 04
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have lowered their price target for Twist Bioscience from $42.14 to $40.00. They cite stable end markets and a cautiously optimistic outlook based on current valuations and improved profit margin expectations.ナラティブ更新 • Sep 19
SynBio And NGS Demand Will Broaden Global Market Reach
Twist Bioscience’s consensus price target increased to $42.14, as a higher future P/E suggests elevated growth expectations despite a decline in net profit margin. What's in the News Collaborated with Synthetic Design Lab, utilizing proprietary tools to support SDL's research activities.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 9/30/2028 | 630 | -61 | 44 | N/A | 8 |
| 9/30/2027 | 539 | -96 | -40 | N/A | 10 |
| 9/30/2026 | 456 | -135 | -82 | N/A | 9 |
| 6/30/2026 | 432 | -137 | -98 | -53 | N/A |
| 3/31/2026 | 409 | -81 | -100 | -56 | N/A |
| 12/31/2025 | 392 | -77 | -87 | -51 | N/A |
| 9/30/2025 | 377 | -78 | -76 | -48 | N/A |
| 6/30/2025 | 362 | -85 | -69 | -51 | N/A |
| 3/31/2025 | 348 | -191 | -65 | -56 | N/A |
| 12/31/2024 | 330 | -197 | -68 | -63 | N/A |
| 9/30/2024 | 313 | -209 | -69 | -64 | N/A |
| 6/30/2024 | 295 | -220 | -75 | -69 | N/A |
| 3/31/2024 | 277 | -192 | -96 | -87 | N/A |
| 12/31/2023 | 262 | -206 | -129 | -111 | N/A |
| 9/30/2023 | 245 | -205 | -170 | -142 | N/A |
| 6/30/2023 | 235 | -209 | -165 | -123 | N/A |
| 3/31/2023 | 228 | -213 | -212 | -134 | N/A |
| 12/31/2022 | 216 | -214 | -233 | -132 | N/A |
| 9/30/2022 | 204 | -218 | -226 | -124 | N/A |
| 6/30/2022 | 184 | -208 | -251 | -158 | N/A |
| 3/31/2022 | 163 | -188 | -212 | -152 | N/A |
| 12/31/2021 | 146 | -165 | -170 | -134 | N/A |
| 9/30/2021 | 132 | -152 | -139 | -112 | N/A |
| 6/30/2021 | 127 | -135 | -124 | -103 | N/A |
| 3/31/2021 | 113 | -123 | -115 | -98 | N/A |
| 12/31/2020 | 101 | -117 | -144 | -132 | N/A |
| 9/30/2020 | 90 | -140 | -152 | -142 | N/A |
| 6/30/2020 | 73 | -147 | -152 | -140 | N/A |
| 3/31/2020 | 66 | -147 | N/A | -139 | N/A |
| 12/31/2019 | 60 | -141 | N/A | -101 | N/A |
| 9/30/2019 | 54 | -108 | N/A | -88 | N/A |
| 6/30/2019 | 47 | -96 | N/A | -81 | N/A |
| 3/31/2019 | 40 | -86 | N/A | -76 | N/A |
| 12/31/2018 | 33 | -77 | N/A | -72 | N/A |
| 9/30/2018 | 25 | -71 | N/A | -66 | N/A |
| 6/30/2018 | 20 | -68 | N/A | -61 | N/A |
| 9/30/2017 | 11 | -59 | N/A | -51 | N/A |
| 9/30/2016 | 2 | -44 | N/A | -39 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: TWST今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: TWST今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: TWST今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: TWSTの収益 ( 17.3% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。
高い収益成長: TWSTの収益 ( 17.3% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: TWSTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/17 21:44 |
| 終値 | 2026/08/17 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Twist Bioscience Corporation 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |